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Pharmacotherapy of the Dental
Patient during Pregnancy and
Lactation
Summary
The pregnant woman and the nursing mother present a special set
of concern for the dental practitioner. Many drugs when taken by a
pregnant patient or a breastfeeding mother can pass the placenta or
breast alveolar cells and enter the bloodstream of the fetus or the human
milk, adversely affecting fetal development or newborn child. The effect
that a medication has on a fetus or a newborn child depends on the type
of drug, the amount of drug taken, the duration of therapy and in
pregnancy the trimester during which the drug was taken.
This is a brief review of the relative risks of drugs commonly used
in dental care for the pregnant patient and the nursing mother. A list
is given of possible harmful drugs in pregnancy and drugs con-
traindicated during breastfeeding.
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Introduction
Medication exposure during pregnancy is very
frequent. An international study in 1992 showed
that antenatally only 14% of women received no
drugs (1). Various studies show marked intercountry
variations in medication habits (2,3). 
In the case of pregnant women when the dental
practitioner needs some therapeutic agents com-
monly used for dental care, he must determine the
potential benefits of the dental therapy, which must
clearly overweigh the potential risk. Pharmacother-
apy during pregnancy is associated with special
problems in the selection of medication and dosage,
primarily due to potential teratogenic or toxic effects
on the fetus by the drug itself and secondly due to
the physiologic adjustments in the mother in
response to pregnancy (4).
Maternal changes in physiology, including fluid
and tissue composition,  occur during pregnancy.
This results in differences in the maternal pharma-
cokinetics of drugs administered during pregnancy.
These modified pharmacokinetic variables ulti-
mately can have an influence on drug metabolites
or toxic compounds in the maternal circulation that
are capable of crossing the placenta and causing
fetal therapeutic and toxic responses to drugs (5).
Pharmacokinetics during pregnancy
Maternal drug absorption may be decreased by
the combination of delayed gastric emptying and
decreased motility. An increase in plasma prog-
esterone level during pregnancy is believed to be
responsible for the reduction in intestinal motility
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(6). There is also a reduction in gastric acid secre-
tions and an increase in mucus secretions, with a
consequent increase in gastric pH. These may alter
the dissolution and absorption of the drug. Absorp-
tion from sites other than the gastrointestinal tract
may also be affected. For example, increased pul-
monary absorption may result from greater minute
ventilation and increased cutaneous absorption as a
result of greater surface area and blood flow (7).
The apparent volume of distribution of many
drugs increases predictably during pregnancy as
maternal plasma volume expands from 30 to 50%
during the first trimester (8). Some of these are
indicated in Table 1. As a result of haemodilution,
plasma albumin declines. The free concentration of
drugs that bind to albumine increases, but the net
effect for most agents is an unaltered free drug
concentration, because more free drug is available
for biotransformation (6). Laurence’s opinion is that
a useful general guide during pregnancy is to main-
tain drug concentrations at the lower end of the
recommended range (5). 
Excretion. Concomitant changes occur in cardiac
output and glomerular filtration rates, which also
increase approximately 30 to 50% during pregnancy
(9). The expanded apparent volume of distribution,
together with an increase in renal clearance leads to
lower maternal circulating concentrations of drugs.
The drugs which are excreted primarily unchanged
in the urine such as amoxycillin, demonstrate
enhanced elimination and lower steady-state serum
concentrations. Its dose should be doubled for sys-
temic infections (but not for urinary tract infections
as penicillins are highly concentrated in the urine)
(5).
Cholestatis frequently develops during pregnan-
cy and may result in decreased hepatic clearance of
drugs that undergo biliary excretion, but their extent
can hardly be quantified (6).
Placental drug transfer
The function of the placenta during gestation is
protection of the conceptus, maintenance of preg-
nancy, possible prevention of maternal rejection 
of the pregnancy, transportation of nutrients and
wastes, metabolism of endogenous and xenobiotic
substances and edocrine activity. However, any
drug or environmental agent that gains access to the
maternal bloodstream should be considered capable
of crossing the placenta and reaching the fetus
unless demonstrated otherwise (7).
In general, lipophilic, unionized, low molecular
weight drugs in their free non-protein bound state
tend to cross the placenta. A major route of placental
drug transfer is a simple diffusion. As with diffusion
across other biological membranes lipophilic drugs
generally cross the placenta more readily than
nonlipophilic compounds. Drugs which are non-
ionized at the physiological pH will diffuse across
the placenta more rapidly than more basic or acidic
compounds. But this distinction is not absolute,
since some drugs which are ionised at physiological
pH such as salicylate (aspirin) rapidly and effi-
ciently reach the fetus (10). The transfer of many
substances across the placenta requires energy or
special carriers.
Some other agents, such as barbiturates, narcotic
analgesics, and local anesthetics, are “flow limited”
in their placental transfer because a decrease in
maternal blood flow to the placenta may reduce the
placental passage of these agents. 
Normal uterine contractions during labor, oxy-
tocic drugs, exogenously administered sympath-
omimetics, or ß-adrenergic receptor blocking agents
all affect maternal and fetal hemodynamics and
therefore may modify maternal drug distribution
and placental transfer. 
Adverse effects of drugs on the fetus
Since 1920 it has been known that external
agents can affect fetal development, when it was
discovered that X-irradiation during pregnancy
could cause fetal malformation or death. The drugs
as causative agents in teratogenesis were recognised
in 1960 with the shocking affair with thalidomide
(11). Drug or chemical exposure during pregnancy
are believed to account for about 1% of all fetal
malformations (12). 
Drugs may act on the embryo and fetus directly
or indirectly. Any drug affecting cell division,
enzymes, protein synthesis or DNA synthesis is
directly a potential teratogen. Indirectly dangerous
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drugs are those acting on the uterus (vasocon-
striction reduce blood supply and cause fetal anoxia;
misoprostol /a synthetic analogue of prostaglandin
E/ cause uterine contraction leading to abortion) and
on the mother’s hormone balance. 
The most vulnerable period for major anatomical
abnormality is that of organogenesis which occurs
during weeks 2-8 of intrauterine life. The adverse
actions of drugs taken by the mother at this time
may result in permanent birth defects (13). After
the organs are formed abnormalities are less
anatomically dramatic, but although developing
fetus continues to be vulnerable to drug effects.
The use of drugs during the final weeks of
pregnancy may have a damaging effect on the fetus
at birth. At that time the newborn has an incom-
pletely developed metabolic system which cannot
process and eliminate drugs rapidly and effectively.
As a result, overdosage may occur. 
Drugs known to be teratogenic, probably or sus-
pected or being teratogenic, are listed in Table 2.
The drugs known to be teratogenic are:
- Ethanol in pregnancy causes impaired fetal
development, associated with small size, abnor-
mal facial development and other physical
abnormalities and mental retardation (14,15,
16).
- Cytotoxic drugs can cause malformations when
used in early pregnancy, but more often lead
to abortion (5).
- Retinoides such as isotretinoine and etreti-
nate, used by dermatologists to treat different
skin diseases (psoriasis, acne etc.), are known
teratogens and cause a high proportion of
serious abnormalities (skeletal deformities) in
exposed fetuses (17).
- Anticonvulsant drugs. The incidence of con-
genital anomalies among babies born to
epileptic women is 2-3 times higher than in
the healthy population. None of the major
anticonvulsants is to be regarded as free from
teratogenic effects and no one drug is clearly
safer than any other in this regard. Phenitoin
(18) can cause cleft lip/palate, valproate (19)
neural tube defects and carbamazepine spina
bifida and hypospadias (a malformation of the
male urethra) (20). However a pregnant
epileptic woman under anticonvulsant treat-
ment has a 90% chance of having a normal
child (with regular controle of serum α-feto-
protein, uterine ultrasonography and diagnos-
tic amniocentois) (21).
- Anticoagulant, warfarin administered in the
first trimester is associated with nasal hypo-
plasia and various central nervous system
abnormalities, affecting roughly 25% of
babies. In the last trimester there is as risk of
intracranial hemorrhage in the baby during
delivery (22). 
For the drugs under suspicion there has been
some reluctance to their use in pregnancy. However,
most large-scale controlled studies conclude that
these agents can be used safely during pregnancy.
But in general the best recommendation is to avoid
any drug during the first trimester.
The drugs probably teratogenic are: cocaine and
sex hormones. The data suggested that cocaine-
-exposed infants may be at increased risk for
congenital malformations (23,24,25) and for the sex
hormones the results of numerous studies have lead
to the conclusion that they are slightly teratogenic
and that caution is needed (26,27).
The US Food and Drug Administration (FDA)
has established five categories for classifying drugs
according to the risks they pose to pregnant women
and their fetuses (28).
These categories, labeled A, B, C, D and X are
listed below (Table 3) with a description for each.
Drugs in category A and B are usually considered
safe for use in pregnancy. Drugs in category C may
be used despite possible risks. Drugs in category D
should usually be avoided and category X is con-
traindicated because the risks involved clearly
outweigh potential benefits. These five categories
provide a guide to the relative safety of drugs
prescribed to pregnant woman.
Selecting drugs for the pregnant dental
patient
In the case of a pregnant patient, the dental
practitioner must determine that the potential ben-
efits of the dental therapy required for her care
outweigh the risks to the fetus.
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The most elective dental procedures must be
postponed until after the pregnancy is over, although
dental treatment for a pregnant woman who has oral
pain, advanced disease or infection should not be
delayed.
The therapeutic agents commonly used in dental
care for pregnant women are local anesthetics, non-
narcotic analgesics, antimicrobials and sedatives/
/anxiolytics. 
Risks associated with specific drug classes
Local anesthetics and the admixture
Local anesthetics are considered relatively safe
for use during pregnancy. Lidocain (Anelok, Lido-
kain) is a widely used local anesthetic agent of the
amide type with low toxic potential. Pregnancy risk
for lidocaine is B. Lidocaine like all local anes-
thetics can cross the placenta. Within the fetus there
is a significant decrease in serum α1-acid gly-
coprotein (the binding proteins for lidocaine and
other basic drugs) and therefore the unbound
(“free”) drug increases. This could cause fetal
depression. The dental practitioner must limit the
dose to the minimum required for effective pain
control (29). 
The adrenaline, a naturally occurring hormone,
pregnancy risk C is generally considered to have no
teratogenic effects when administered with dental
anesthetics. Adrenaline can stimulate cardiovascular
functions and its administration demands careful
technique and proper dosing (30). Adrenaline may
delay the second stage of labor in a pregnant woman
because the drug inhibits spontaneous or oxytocin-
induced uterine contractions. It may also cause
anoxia to the fetus (31).
Non-narcotic analgesics
For management of oral pain during pregnancy,
among a number of peripherally acting analgesics,
paracetamol (acetaminophen) is considered to be
the best choice (32,33). Pregnancy risk for parac-
etamol is B. The second analgesic is aspirin,
pregnancy risk D. Aspirin has widespread use in
pregnant woman, and in moderate doses has shown
no evidence of  teratogenesis in humans. There are
very few reports in which aspirin can be implicated
as a human teratogen (34,35,36). Possibly the
increased production of prostaglandins during
pregnancy overrides the effects of aspirin in the
usual dosages. But aspirin and other nonsteroidal
anti-inflammatory drugs (NSAID) such as ibuprofen
and naproxen should be avoided particularly during
the third trimester of pregnancy because they have
the common mechanism  of inhibiting prostaglandin
synthesis. By blocking synthesis of the prosta-
glandins involved in induction of labor, NSAID may
prolong pregnancy. Additionally, prostaglandin
inhibitors may cause constriction of the ductus
arteriosus in the fetus, resulting in pulmonary
hypertension in the infant. The role of aspirin as an
antithrombotic agent and its ability to promote
bleeding mean that it should be very definitely
avoided at parturition, to avoid delivery compli-
cations and postpartum hemorrage in the mother
(37).
Antimicrobials
Penicillin G, penicillin V, ampicillin, amoxicillin
and cephalosporins (all pregnancy risk B) are gen-
erally thought to be safe during pregnancy. As
remarked above the pharmacokinetic of ampicillin
and amoxicillin is altered in pregnant women and
this can lead to  lower plasma concentrations of the
drug when compared with nonpregnant women
(38). Pregnancy significantly increases the elim-
ination rate of ampicillin (39). Similar results of the
significantly faster elimination rate have  also been
demonstrated in a pharmacokinetic study on preg-
nant women and phenoxymethylpenicillin (Peni-
cillin V) (40). Erythromycin (except erythromycin
estolate) (41,42), clindamicin - both pregnancy risk
C, and metronidazole - pregnancy risk B, are
believed to have minimal risk (43). 
The greatest concern regarding antimicrobial use
is the agents that have limited indications in
dentistry: aminoglycosides (gentamycin) cross the
placenta and might theoretically cause otological
and perhaps nephrological damage to the fetus. No
proven cases of intrauterine damage by gentamicin
and tobramycin have been recorded (41).
Tetracycline therapy in the second and third
trimester of pregnancy have been implicated for
causing tooth discoloration and inhibition of bone
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development in infants. In view of their effects on
the teeth and the bones, as well as in view of an
increased risk of potentially fatal fatty liver degen-
eration in pregnant women, tetracycline prepara-
tions should not be prescribed during pregnancy
with the exception of a vital indication (44,45).
Chloramphenicol is contraindicated in preg-
nancy because of maternal toxicity and fetal
circulatory failure called gray baby syndrome (46).
Sedatives - anxiolytics
Benzodiazepines (pregnancy risk D) are anx-
iolytic drugs commonly prescribed in pregnancy.
They readily pass from the mother to the fetus.
Pregnant women may have some risk of congenital
malformation if exposed to benzodiazepines during
the 1 st trimester, although data are contradictory
and any real effect would appear to be minimal
(47,48). The pregnant women should avoid ben-
zodiazepines if possible, during late pregnancy and
labour, because floppiness, apnea and withdrawal in
the infant can pose obvious clinical problems (49).
A single exposure to a clinically acceptable dose of
any benzodiazepine, as compared to chronic therapy
throughout pregnancy, would have minimal risk
(50).
Drugs and breast milk
Breastfeeding of the newborn child has increased
during the past ten years in the US and European
countries. This, in  combination with the explosive
growth in the number of new pharmacologic agents
concerns over environmental contaminants could be
a risk for the breastfeeding infant. Medical pro-
fessionals too often simply discourage breastfeeding
instead of investigating whether the drug enters
breast milk and poses a risk to child or not (51,52).
Human milk represents a complex solution of
proteins, carbohydrates, fat, and liquid with a
composition similar to that in serum. Its com-
position varies during the weeks and the months of
lactation as well as during a single feeding. Human
milk has a pH of approximately 7.0, which influnces
the distribution of drugs from the maternal cir-
culation into milk. To enter human milk, a drug
leaves the maternal circulation and enters the breast
alveolar cells by diffusion across cell membranes or
into water-filled channels or through binding to
carrier proteins. Since milk is more acidic than
plasma basic compouds may be slightly concen-
trated in this fluid, and the concentration of acidic
compounds in milk is lower than in plasma. Non-
electrolites, such as ethanol and urea, readily enter
breast milk and reach the same concentration as in
plasma, independent of the pH of the milk (53). For
most drugs, the milk concentration is similar to that
in the maternal circulation. The usual percentage of
the maternal dose transferred to the infant ranges
from 0.05% to 2%. Most drugs taken by the mother
pose no hazard to the child, but there are exceptions.
Practical measures can be used to minimize the
passage of drug into milk, e.g., breastfeeding just
before the administration of medication so that a
significant amount of the drug can be eliminated
before the next feeding. Few drugs are considered
to be contraindicated during breastfeeding and
should be avoided. For some drugs a temporary
cessation of breastfeeding is required, some of them
must be given with caution during breastfeeding and
for some with unknown drug effects care is
necessary (Table 4).
When dental treatment is needed to maintain a
breastfeeding womans oral health selecting the
safest agents is the basic principle of therapy (54).
The therapeutic agents most commonly used in
dental care are local anesthetics. Low concentrations
of lidocaine and its metabolite monoethylglycinexy-
lidide have been found in breast milk after a dental
procedure, but no risk seems to be involved (55).
Tetracaine (20 times as toxic as procaine) marked
serious systemic side effects can develop owing to
rapid absorption following topical use (56).
For alleviation of the mother’s oral pain periph-
ererally acting analgesic-antipyretic can be used.
However salicylates are distributed into breast milk
and the use of aspirin should be avoided during
breastfeeding (possible association with Reyes syn-
drome!) (5). Paracetamol is also excreted into
breast milk in low concentrations, but no adverse
effects have been reported, so it can be a drug of
choice.
Administration of any of the central nervous
system depressants commonly used for sedation is
problematic. Benzodiazepines are safe if their use is
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brief. Prolonged use may cause a somnolence or
poor suckling (50).
The infection of the orodental system in the
breastfeeding mother must also be treated, but only
a few antiinfectives pose no hazard (57).
Penicillins and cephalosporins are excreted in
breast milk and their use, particularly penicillin G
and V, in breastfeeding women may sensitize the
infant to penicillins (31).
Aminoglycosides are excreted in small amounts
in breast milk. An alternative feeding method is
recommended during therapy, because the half-life
of aminoglycosides is prolonged in neonates owing
to the immaturity of their renal system (58).
Tetracyclines are excreted in breast milk and
should not be used in breast feeding women because
of the risk of discoloration of teeth, enamel defects
and retardation of the childs bone growth (59).
Chloramphenicol is unsafe. The drug is excreted
in milk in low concentrations, posing a risk of bone
marow depression and a slight risk of “gray baby
sindrome” (60).
Clindamycin, lincomycin, metronidazole and
sulphonamide should be avoided (5).
Erythromicin can be used with cautioun (30).
Conclusion
When treating pregnant patients or breastfeeding
mothers the dental practitioners needs to determine
that the potential benefits of the drug required for
the mothers dental care outweigh the risks to the
fetus or neonate.
Some drugs routinely used are more unsafe than
others and these should be avoided.
A list of unsafe drugs is not practicable, because
much depends on the timing of the drug admin-
istration (during first, second or third trimester), the
dosage and the duration of therapy. Dental prac-
titioners, who usually use drugs with short meta-
bolic half-lives, administered for limited periods
and in reduced dosages, are less likely to cause
complications during pregnancy and lactation.
